PROCEPT BioRobotics Expands HYDROS Robotic System Internationally
Event summary
- PROCEPT BioRobotics launched the HYDROS Robotic System internationally on March 12, 2026.
- HYDROS is the first AI-enabled robotic platform for Aquablation therapy, treating benign prostatic hyperplasia (BPH).
- The system leverages AI-interpreted ultrasound imaging and robotic precision for personalized treatment.
- Initial international expansion targets the UK, with plans for further global rollout.
The big picture
PROCEPT BioRobotics’ international expansion of the HYDROS Robotic System marks a strategic move to broaden access to AI-driven BPH treatment. The launch aligns with the growing trend of AI integration in surgical robotics, positioning PROCEPT as a key player in the evolving urology market. The system’s ability to deliver personalized, anatomy-specific therapy could set a new standard for BPH treatment, potentially reshaping the competitive landscape.
What we're watching
- Adoption Pace
- The pace at which HYDROS gains traction in international markets, particularly the UK.
- Regulatory Approvals
- Whether HYDROS secures additional regulatory clearances beyond the UK.
- Competitive Response
- How competitors in the BPH treatment space react to PROCEPT’s AI-enabled robotic solution.
Related topics